Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
March, 2026
March 2026
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  

Drugs

Lina Elfaki: Anticoagulation Medications - A Critical Component of Patient Safety
Dec 25, 2025, 03:33 | Drugs
Lina Elfaki: Anticoagulation Medications - A Critical Component of Patient Safety
Lina Elfaki, Senior clinical pharmacist, shared on LinkedIn: "Anticoagulation Medications: A Critical Component of Patient…
Nadeem Rais Explains: A Clinical Comparison of AntiPlatelets vs AntiCoagulants
Dec 23, 2025, 09:01 | Drugs
Nadeem Rais Explains: A Clinical Comparison of AntiPlatelets vs AntiCoagulants
Nadeem Rais, Clinical Pharmacist at NMC Healthcare, shared a post on LinkedIn: "AntiPlatelets vs AntiCoagulants Blood…
Ahmed Koriesh on Comparison of Apixaban and Warfarin
Dec 23, 2025, 05:23 | Drugs
Ahmed Koriesh on Comparison of Apixaban and Warfarin
Ahmed Koriesh, Director Hospital Neurology Service at Cleveland Clinic Florida, shared on LinkedIn: ''How many…
Stroke-Associated Letal Outcome with Hympavzi: Michael Makris on Pfizer's Announcement
Dec 23, 2025, 05:14 | Drugs
Stroke-Associated Letal Outcome with Hympavzi: Michael Makris on Pfizer's Announcement
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at the University of Sheffield, Editor-in-Chief of…
Jose Ricardo Soares: Genomic Testing for All Patients Considered for Clopidogrel in UK
Dec 22, 2025, 16:44 | Drugs
Jose Ricardo Soares: Genomic Testing for All Patients Considered for Clopidogrel in UK
Jose Ricardo Soares, Relief Pharmacist at Uniphar Group, reposted from University of Liverpool on LinkedIn:…
Abdulla A. Damluji: Cardiovascular Outcomes with Tirzepatide Versus Dulaglutide in Type 2 Diabetes
Dec 22, 2025, 12:39 | Drugs
Abdulla A. Damluji: Cardiovascular Outcomes with Tirzepatide Versus Dulaglutide in Type 2 Diabetes
Abdulla A. Damluji, Director of the Cardiovascular Center on Aging at Cleveland Clinic, has shared…
Abdul Mannan - Breaking in Haem: Andexanet Alfa Withdrawn from US Market
Dec 20, 2025, 11:13 | Drugs
Abdul Mannan - Breaking in Haem: Andexanet Alfa Withdrawn from US Market
Abdul Mannan, Consultant Haematologist at Betsi Cadwaladr University Health Board, shared on LinkedIn: "Breaking in…
Specific Reversal Agents for Direct Oral Anticoagulants in Neurosurgical Emergencies
Dec 20, 2025, 07:41 | Drugs
Specific Reversal Agents for Direct Oral Anticoagulants in Neurosurgical Emergencies
RPTH Journal shared a post on LinkedIn: "In emergency neurosurgery, rapid DOAC reversal is critical. This…
Plasma-Derived Therapy for Hemophilia in The Updated European Medicines Agency’s Union List
Dec 18, 2025, 14:15 | Drugs
Plasma-Derived Therapy for Hemophilia in The Updated European Medicines Agency’s Union List
Deborah Hibbett, Senior Vice President, Head of Global Corporate Affairs and Sustainability, Plasma-Derived Therapies at…
Wolfgang Miesbach: Rituximab Dose Optimization in iTTP - Why Standard Dose is Preferred?
Dec 17, 2025, 23:55 | Drugs
Wolfgang Miesbach: Rituximab Dose Optimization in iTTP - Why Standard Dose is Preferred?
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared on LinkedIn: "ASH25 Data: Rituximab Dose…
All: 83 Posts: 11 - 20
NewsFeed